keyword
MENU ▼
Read by QxMD icon Read
search

abuse deterrent

keyword
https://www.readbyqxmd.com/read/28333577/abuse-deterrent-opioid-formulations-329
#1
Ryann O'Neill, Kimberly Lor, Jennifer Pruskowski
No abstract text is available yet for this article.
March 23, 2017: Journal of Palliative Medicine
https://www.readbyqxmd.com/read/28318019/corrigendum-the-effect-of-an-abuse-deterrent-opioid-formulation-oxycontin-on-opioid-abuse-related-outcomes-in-the-postmarketing-setting
#2
(no author information available yet)
No abstract text is available yet for this article.
April 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28277802/oxycodone-extended-release-capsules-for-the-treatment-of-chronic-pain
#3
Sebastiano Mercadante
As a consequence of greater prescription opioid utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious risks. Associated new formulations may be safer. Areas covered: The introduction of abuse-deterrent opioid formulations and continuous programs to improve opioid prescribing practices may limit the opioid abuse and its consequences. Oxycodone extended release capsules are an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e...
March 10, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28251526/management-of-patients-on-abuse-deterrent-opioids-in-the-ambulatory-surgery-setting
#4
REVIEW
Nalini Vadivelu, Daniel Chang, Leandro Lumermann, Thomas Suchy, Matthew M Burg, Manuel L Fontes
PURPOSE OF REVIEW: The use of prescription opioids for acute and chronic pain has become more prevalent than ever, and concurrent with the increased prescribing of opioids, there has been a steady increase in opioid abuse. Abuse is commonly associated with physical or chemical manipulation of the original opiate to provide more rapid onset of the active ingredient. RECENT FINDINGS: This growing national public health concern has led to the development of various abuse-deterring opioids with the intent of decreasing the diversion of opioids from their prescribed use...
February 2017: Current Pain and Headache Reports
https://www.readbyqxmd.com/read/28243142/secular-trends-in-opioid-prescribing-in-the-usa
#5
Edmund J Pezalla, David Rosen, Jennifer G Erensen, J David Haddox, Tracy J Mayne
Opioid abuse and misuse in the USA is a public health crisis. The use of prescription opioid analgesics increased substantially from 2002 through 2010, then plateaued and began to decrease in 2011. This study examined prescriptions of branded and generic immediate- and extended-release opioid analgesics from 1992 to 2016. This was juxtaposed against state and federal policies designed to decrease overutilization and abuse, as well as the launch of new opioid products, including opioids with abuse-deterrent properties (OADPs)...
2017: Journal of Pain Research
https://www.readbyqxmd.com/read/28162702/-457-effectiveness-of-hysingla-%C3%A2-er-a-once-daily-single-entity-hydrocodone-with-abuse-deterrent-properties-in-treating-chronic-nonmalignant-and-nonneuropathic-pain-in-patients-with-depression-and-anxiety
#6
S Lynch, L Taber, E He, R Shah
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162693/-442-pharmacodynamic-data-assessing-the-abuse-potential-of-a-novel-abuse-deterrent-oxycodone-formulation-eli-200-compared-to-oxycodone-immediate-release-oral-intact-eli-200-and-placebo-in-healthy-non-dependent-recreational-opioid-users-following-intranasal
#7
B Setnik, K Schoedel, C Bartlett, C Dick, N Hakim, P Geoffroy
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162691/-444-clinical-results-of-an-abuse-potential-study-with-remoxy-%C3%A2-an-abuse-deterrent-extended-release-product
#8
L Webster, N Friedmann
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162680/-430-bioequivalence-and-food-effect-of-a-novel-abuse-deterrent-ad-extended-release-er-morphine-product-candidate-compared-with-a-currently-available-non-ad-er-morphine-product
#9
J Dayno, J Lawler, G Niebler, K Lindhardt
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162673/-425-dissolution-studies-in-the-presence-of-alcohol-with-an%C3%A2-abuse-deterrent-extended-release-morphine-product-candidate
#10
T Elhauge, L Kristensen, J Dayno, K Lindhardt
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162671/-422-pharmacodynamic-effects-from-a-category-3-intranasal-human-abuse-potential-study-of-an-abuse-deterrent-extended-release-morphine-product-candidate-in-nondependent-recreational-opioid-users
#11
L Webster, M Smith, J Lawler, K Lindhardt, J Dayno
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162496/-263-a-model-to-quantify-potential-medical-events-avoided-and-cost-savings-from-abuse-deterrent-opioids
#12
A White, M Yenikomshian, M Carson, E Masters, C Roland
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/28162368/-145-relative-abuse-of-abuse-deterrent-formulations-via-alternative-oral-routes
#13
S Butler, R Black, A Fleming
No abstract text is available yet for this article.
April 2016: Journal of Pain: Official Journal of the American Pain Society
https://www.readbyqxmd.com/read/27983881/hysingla%C3%A2-er-a-once-daily-single-entity-hydrocodone-with-abuse-deterrent-properties-in-treating-chronic-nonmalignant-and-nonneuropathic-pain-in-patients-with-osteoarthritis
#14
MULTICENTER STUDY
Louise Taber, Stacy Baldridge, Ellie He, Steven R Ripa
OBJECTIVES: Osteoarthritis (OA)-related chronic pain is associated with physical and psychosocial impairment as well as poorer quality of life. There is limited literature on long-term opioid therapy in OA patients. This post hoc analysis of OA patients assessed the long-term safety and effectiveness of a once-daily, single-entity, extended-release formulation of hydrocodone (HYD) with abuse-deterrent properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which other treatment options are inadequate...
January 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/27960575/assessing-the-impact-of-abuse-deterrent-opioids-ados-identifying-epidemiologic-factors-related-to-new-entrants-with-low-population-exposure
#15
COMPARATIVE STUDY
Carl L Roland, Beatrice Setnik, David A Brown
OBJECTIVE: Prescription opioid misuse and abuse is a serious public health concern that can lead to overdose, addiction, and death. The development of opioid formulations designed to deter misuse and abuse is considered an important step towards addressing the problem, but the extent to which abuse-deterrent opioids (ADOs) actually deter abuse in the community requires confirmation through epidemiologic studies. Epidemiologic evaluations of misuse and abuse present several unique challenges related to study design, sources of data, and methodology, particularly for new entrant ADOs with low population exposure...
January 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/27956191/effects-of-excipients-and-curing-process-on-the-abuse-deterrent-properties-of-directly-compressed-tablets
#16
Ziyaur Rahman, Ahmed S Zidan, Maxwell Korang-Yeboah, Yang Yang, Akhtar Siddiqui, Diaa Shakleya, Mansoor A Khan, Celia Cruz, Muhammad Ashraf
The objective of the present investigation was to understand the effects of excipients and curing process on the abuse deterrent properties (ADP) of Polyox™ based directly compressible abuse deterrent tablet formulations (ADFs). The excipients investigated were lactose (monohydrate or anhydrous), microcrystalline cellulose and hydroxypropyl methylcellulose. The ADPs studied were tablet crush resistance or hardness, particle size distribution following mechanical manipulation, drug extraction in water and alcohol, syringeability and injectability...
December 9, 2016: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/27915497/current-and-future-development-of-extended-release-abuse-deterrent-opioid-formulations-in-the-united-states
#17
REVIEW
Lynn R Webster, John Markman, Edward J Cone, Gwendolyn Niebler
Prescription opioid misuse and abuse in the United States (US) is epidemic and is a major burden on health-care resources and costs to society. The need to significantly reduce the risks of prescription opioid misuse and abuse must be balanced with the important needs of patients with chronic pain who may benefit from treatment with opioids. The use of abuse-deterrent formulations (ADFs) of prescription opioids is one approach that could reduce the risk of prescription opioid abuse and misuse while maintaining access to opioids...
January 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/27897471/use-of-risk-mitigation-practices-by-family-nurse-practitioners-prescribing-opioids-for-the-management-of-chronic-nonmalignant-pain
#18
Sahil Chaudhary, Peggy Compton
BACKGROUND: Ongoing opioid analgesic use in patients suffering from chronic nonmalignant pain (CNMP) has been associated with the development of opioid misuse, abuse, addiction, and overdose. To prevent these adverse outcomes, it is important that family nurse practitioners (FNPs) implement recommended risk mitigation practices (RMPs) when treating CNMP patients with opioids. METHODS: A national sample of 856 FNPs was invited to answer an online survey about their utilization of opioids and RMPs in treating CNMP...
January 2017: Substance Abuse
https://www.readbyqxmd.com/read/27873179/oxycodone-deterx-%C3%A2-a-novel-abuse-deterrent-extended-release-analgesic-option-for-the-treatment-of-patients-with-chronic-pain
#19
REVIEW
Jeff Gudin
BACKGROUND: Extended-release (ER) opioid analgesics are commonly used to provide safe and effective pain relief to treat pain severe enough to require around-the-clock, long-term dosing. These ER opioid formulations usually contain more drug per dosage unit than immediate-release (IR) agents, and therefore bring with them challenges related to both opioid abuse and misuse, often through manipulation of the dosage form. Oxycodone DETERx(®) (Xtampza(®) ER, Collegium Pharmaceutical, Inc...
December 2016: Pain and Therapy
https://www.readbyqxmd.com/read/27832472/oxycodone-deterx-%C3%A2-er-capsules-a-review-in-severe-chronic-pain
#20
Yvette N Lamb, Karly P Garnock-Jones, Susan J Keam
Oxycodone DETERx (®) extended-release (ER) capsules (Xtampza(®) ER), an abuse-deterrent formulation of oxycodone as the myristate salt, are approved in the USA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. This narrative review discusses the clinical efficacy and tolerability of the oxycodone DETERx (®) ER capsule formulation in the management of severe pain, and provides an overview of pharmacokinetics, abuse-deterrent properties and alternative administration options...
December 2016: Drugs
keyword
keyword
43163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"